Liquidia CORP 10-Q quarterly reports

Liquidia Corporation reported a substantial increase in product sales driven by YUTREPIA, alongside significant investments in research and development and ongoing litigation.

Liquidia Corporation announced a substantial increase in revenue for the first quarter of 2026, driven by strong product sales of YUTREPIA.

Liquidia Corporation reports significant revenue growth driven by the commercial launch of YUTREPIA, alongside a reduced net loss, but faces ongoing patent and trade secret litigation and increased debt.

Liquidia Corporation reports increased losses and expenses in Q2 2025 despite the commercial launch of its key drug YUTREPIA, as it navigates multiple high-stakes patent and trade secret litigations.

Liquidia Corporation reports Q1 2025 results with a net loss of $38.4 million and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Liquidia Corporation received tentative FDA approval for YUTREPIA, while facing patent litigation and securing significant funding through a public offering and a private placement.

Liquidia Corporation's second quarter 2024 results reveal a net loss of $27.9 million, impacted by increased operating expenses and ongoing litigation, while the company continues to advance its pipeline.

Liquidia Corporation's first quarter 2024 results show a significant net loss, increased operating expenses, and a substantial cash infusion from a private placement, all while navigating complex patent litigation and advancing its product pipeline.